WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

R^1 is selected from the group consisting of:

(1) -C_{1-6}alkyl,

(2) -C_{2-6} alkenyl,

(3) -C_{2-6} alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, which is unsubstituted or substituted with a group selected from:

(i) halo,

(ii) -C_{1-6}alkyl,

(iii) -C_{2-6} alkenyl,

(iv) -C_{2-6} alkynyl,

(v) -OH, and

(vi) -O-C_{1-6}alkyl,

(4) hydrogen;

R^2 is selected from the group consisting of:

(1) R^4-$S(O)_2N(R^7)$-,

wherein R^4 is independently selected from the group consisting of:

(a) -C_{1-6}alkyl,

(b) -C_{2-6} alkenyl,

(c) -C_{2-6} alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with 1-6 fluoro,

(d) phenyl, and

(e) benzyl,

wherein R^7 is independently selected from the group consisting of:

(a) hydrogen,

(b) -C_{1-6}alkyl,

(c) -C_{2-6} alkenyl,

(d) -C_{2-6} alkynyl,

(2)



,

wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

(a) hydrogen,

(b) -CN,

(c) halo,

(d) -C_{1-6}alkyl,

(e) -C_{2-6} alkenyl, and

(f) -C_{2-6} alkynyl

R^3 is selected from the group consisting of:



;

R^{6a}, R^{6b}, and R^{6c} are independently selected from the group consisting of:

(1) hydrogen, and

(2) halogen;

R^5 is selected from the group consisting of:

(1) -C_{1-6}alkyl,

(2) -C_{2-6} alkenyl,

(3) -C_{2-6} alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, and

(4) hydrogen;

R^{13} is selected from the group consisting of -CH=CH- and -O-;

R^9 and R^{10} are independently selected from the group consisting of:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{2-6} alkenyl,

(4) C_{2-6} alkynyl, wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl,

or R^9 and R^{10} may be joined together to form a pyrrolidine or piperidine ring which is unsubstituted or substituted with -C_{1-6}alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, -C_{1-6}alkyl-O-C_{1-6}alkyl, phenyl or pyridyl;

R^{11} is selected from the group consisting of:

(1) -OH,

(2) -O-C_{1-6}alkyl,

(3) -O-C_{1-6}alkyl-phenyl,

(4) -O-phenyl, and

(5) phenyl;

R^{12} is selected from the group consisting of:

(1) -NR^9R^{10}, and

(2) -OH;

m is independently 0, 1, or 2;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 of the formula II:



II

wherein:

R^1 is selected from the group consisting of:

(1) C_{1-6}alkyl, unsubstituted or substituted with phenyl, and

(2) hydrogen;

R^2 is selected from the group consisting of:

(1) R^4-$S(O)_2N(R^7)$-,

wherein R^4 is independently selected from the group consisting of:

(a) C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) phenyl, and

(c) benzyl,

wherein R^7 is independently selected from the group consisting of:

(a) hydrogen, and

(b) -C_{1-6}alkyl,

(2)



,

wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

(a) hydrogen,

(b) -CN,

(c) halo, and

(d) -C_{1-6}alkyl,

R^5 is selected from the group consisting of:

(1) C_{1-6}alkyl, unsubstituted or substituted with phenyl, and

(2) hydrogen;

R^9 and R^{10} are independently selected from the group consisting of:

(1) hydrogen, and

(2) C_{1-6}alkyl, unsubstituted or substituted with phenyl;

R^{11} is selected from the group consisting of:

(1) -OH,

(2) -O-phenyl, and

(3) phenyl.

3. The compound of Claim 1 of the formula III:



III

wherein:

R^1 is selected from the group consisting of:

(1) C_{1-6}alkyl, unsubstituted or substituted with phenyl, and

(2) hydrogen;

R^2 is selected from the group consisting of:

(1) R^4-$S(O)_2N(R^7)$-,

wherein R^4 is independently selected from the group consisting of:

(a) C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) phenyl, and

(c) benzyl,

wherein R^7 is independently selected from the group consisting of:

(a) hydrogen, and

(b) -C_{1-6}alkyl,

(2)



wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

(a) hydrogen,

(b) -CN,

(c) halo, and

(d) -C_{1-6}alkyl,

R^5 is selected from the group consisting of:

(1) C_{1-6}alkyl, unsubstituted or substituted with phenyl, and

(2) hydrogen;

R^{11} is selected from the group consisting of:

(1) -OH,

(2) -O-phenyl, and

(3) phenyl.

4. The compound of Claim 1 wherein R^1 is selected from the group consisting of:

(1) benzyl,

(2) phenyl-ethyl-,

(3) methyl, and

(4) hydrogen.

5. The compound of Claim 1 wherein R^2 is CH_3-$S(O)_2N(CH_3)$-.

6. The compound of Claim 1 wherein R^2 is cyano-phenyl-.

7. The compound of Claim 1 wherein R^5 is methyl.

8. The compound of Claim 1 wherein R^9 and R^{10} are independently selected from the group consisting of:

(1) hydrogen, and

(2) methyl.

9. The compound of Claim 1 wherein R^{11} is -OH.

10. A compound which is selected from the group consisting of:



	
	
	
	
	

and pharmaceutically acceptable salts thereof.

11. A pharmaceutical composition comprising an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method for inhibition of β-secretase activity in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

13. A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

14. A method for preventing, controlling, ameliorating or reducing the risk of Alzheimers disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.